Albert Chiou, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chiou’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A131904 · Current
Licensed to practise in California · since 2014 · expires 2028-04-30 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$47,355
Medicare paid this office $47,355 for 386 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 104 | $12,284 | $78 |
| Short return visit (20+ min) | 125 | $8,775 | $57 |
| Destruction of precancer skin growth, 1 growth | 125 | $7,583 | $43 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 147 | $4,085 | $28 |
| Destruction of skin growth, 1-14 growths | 45 | $3,104 | $60 |
See all 12 services
| Return visit (30+ min) | 104 | $12,284 | $78 |
| Short return visit (20+ min) | 125 | $8,775 | $57 |
| Destruction of precancer skin growth, 1 growth | 125 | $7,583 | $43 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 147 | $4,085 | $28 |
| Destruction of skin growth, 1-14 growths | 45 | $3,104 | $60 |
| New patient visit (30+ min) | 42 | $3,013 | $72 |
| New patient visit (45+ min) | 21 | $2,316 | $110 |
| Biopsy of related skin growth, first growth | 57 | $1,416 | $21 |
| Destruction of precancer skin growth, 2-14 growths | 104 | $1,193 | $2 |
| Biopsy of related skin growth, each additional growth | 16 | $587 | $21 |
| Punch biopsy, first skin growth | 13 | $545 | $42 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 21 | $326 | $15 |
Procedures Medicare counted
| Removal of skin lesions | 391 | More than 84% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 106 | More than 76% of doctors who do this |
Who their Medicare patients are
386 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 18% · Women 59% · Also on Medicaid 18% · Health risk score 1.33. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 67% · Diabetes 26% · Coronary heart disease 22% · Chronic kidney disease 21% · Atrial fibrillation 19% · Cancer 18% · Depression 16% · Heart failure 13% · COPD 9% · Dementia 9% · Stroke 7%.
The office billed $228,006, Medicare allowed $65,643 and paid $47,355; for 1,603 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 386 | 1,603 | 76 | 1.33 | $228,006 | $47,355 |
| 2023 | 430 | 2,019 | 75 | 1.28 | $325,971 | $72,749 |
| 2022 | 483 | 2,745 | 75 | 1.22 | $504,187 | $117,767 |
| 2021 | 387 | 2,473 | 73 | 1.22 | $520,289 | $120,917 |
| 2020 | 320 | 2,063 | 73 | 1.17 | $437,341 | $85,546 |
| 2019 | 372 | 2,295 | 74 | 1.32 | $656,872 | $113,354 |
| 2018 | 483 | 2,343 | 73 | 1.48 | $636,747 | $108,895 |
| 2017 | 124 | 369 | 73 | 1.37 | $102,633 | $17,975 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Return visit (30+ min) | 155 | $19,279 | $87 |
| Short return visit (20+ min) | 164 | $12,505 | $62 |
| Destruction of precancer skin growth, 1 growth | 162 | $10,203 | $46 |
| Biopsy of related skin growth, first growth | 69 | $4,185 | $52 |
| Destruction of skin growth, 1-14 growths | 53 | $4,084 | $69 |
| Destruction of precancer skin growth, 2-14 growths | 141 | $3,546 | $4 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 103 | $3,017 | $29 |
| New patient visit (30+ min) | 37 | $2,659 | $72 |
| New patient visit (45+ min) | 20 | $1,970 | $98 |
| Destruction of precancer skin growth, 15 or more growths | 14 | $1,624 | $108 |
| Injection into skin growth, 1-7 growths | 21 | $1,202 | $32 |
| Biopsy of related skin growth, each additional growth | 21 | $1,032 | $36 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $16 | None |
2022: 16 services
| Return visit (30+ min) | 189 | $25,870 | $95 |
| Short return visit (20+ min) | 234 | $20,804 | $68 |
| Destruction of precancer skin growth, 1 growth | 208 | $13,829 | $45 |
| Destruction of skin growth, 1-14 growths | 77 | $8,424 | $82 |
| Biopsy of related skin growth, first growth | 124 | $7,489 | $55 |
| New patient visit (30+ min) | 70 | $5,262 | $75 |
| Destruction of precancer skin growth, 2-14 growths | 173 | $4,854 | $4 |
| New patient visit (45+ min) | 32 | $3,902 | $122 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 16 | $3,621 | $226 |
| Destruction of precancer skin growth, 15 or more growths | 17 | $3,219 | $129 |
| Biopsy of related skin growth, each additional growth | 36 | $1,799 | $32 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 12 | $1,525 | $90 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 50 | $1,468 | $29 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 11 | $1,232 | $103 |
| Injection into skin growth, 1-7 growths | 14 | $940 | $32 |
| Telehealth originating site facility fee | 23 | $575 | $20 |
2021: 13 services
| Return visit (30+ min) | 165 | $27,973 | $104 |
| Short return visit (20+ min) | 190 | $16,598 | $66 |
| Destruction of precancer skin growth, 1 growth | 193 | $11,647 | $43 |
| Biopsy of related skin growth, first growth | 124 | $8,268 | $56 |
| New patient visit (45+ min) | 45 | $6,141 | $136 |
| Destruction of skin growth, 1-14 growths | 56 | $5,899 | $87 |
| New patient visit (30+ min) | 57 | $4,545 | $80 |
| Destruction of precancer skin growth, 2-14 growths | 158 | $4,408 | $5 |
| Destruction of precancer skin growth, 15 or more growths | 23 | $3,752 | $125 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 11 | $2,977 | $271 |
| Biopsy of related skin growth, each additional growth | 38 | $2,317 | $39 |
| Punch biopsy, first skin growth | 15 | $1,500 | $94 |
| Telehealth originating site facility fee | 27 | $822 | $20 |
2020: 16 services
| Return visit (30+ min) | 185 | $21,842 | $84 |
| Destruction of precancer skin growth, 1 growth | 137 | $8,084 | $44 |
| Short return visit (20+ min) | 109 | $7,332 | $53 |
| Biopsy of related skin growth, first growth | 96 | $6,769 | $55 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 15 | $4,621 | $257 |
| Biopsy of related skin growth, each additional growth | 37 | $3,728 | $40 |
| New patient visit (30+ min) | 42 | $3,530 | $84 |
| Destruction of precancer skin growth, 2-14 growths | 117 | $3,494 | $5 |
| Destruction of skin growth, 1-14 growths | 17 | $1,791 | $81 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $1,666 | $128 |
| New patient visit (15+ min) | 29 | $1,603 | $55 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 11 | $1,381 | $99 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 11 | $1,325 | $95 |
| Punch biopsy, first skin growth | 15 | $1,015 | $68 |
| Telehealth originating site facility fee | 35 | $870 | $21 |
| Injection into skin growth, 1-7 growths | 12 | $532 | $28 |
2019: 11 services
| Return visit (30+ min) | 163 | $24,050 | $89 |
| Biopsy of related skin growth, first growth | 107 | $10,909 | $79 |
| Destruction of precancer skin growth, 1 growth | 149 | $9,897 | $44 |
| Short return visit (20+ min) | 129 | $9,756 | $59 |
| New patient visit (30+ min) | 93 | $8,402 | $90 |
| Destruction of precancer skin growth, 2-14 growths | 123 | $4,129 | $5 |
| Biopsy of related skin growth, each additional growth | 44 | $3,966 | $48 |
| New patient visit (15+ min) | 48 | $3,234 | $67 |
| Destruction of precancer skin growth, 15 or more growths | 14 | $2,827 | $141 |
| Punch biopsy, first skin growth | 24 | $2,639 | $110 |
| Injection into skin growth, 1-7 growths | 15 | $698 | $35 |
2018: 11 services
| Return visit (30+ min) | 148 | $18,747 | $90 |
| Short return visit (20+ min) | 174 | $16,617 | $62 |
| Biopsy of single growth of skin and/or tissue | 155 | $15,216 | $85 |
| New patient visit (30+ min) | 151 | $13,633 | $90 |
| Destruction of precancer skin growth, 1 growth | 163 | $10,434 | $46 |
| New patient visit (15+ min) | 122 | $7,070 | $58 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 14 | $3,912 | $279 |
| Destruction of precancer skin growth, 2-14 growths | 129 | $3,448 | $5 |
| Biopsy of each additional growth of skin and/or tissue | 50 | $1,997 | $28 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 11 | $1,750 | $125 |
| Injection into skin growth, 1-7 growths | 11 | $889 | $42 |
2017: 8 services
| New patient visit (30+ min) | 38 | $3,456 | $91 |
| Biopsy of single growth of skin and/or tissue | 37 | $3,065 | $81 |
| New patient visit (15+ min) | 41 | $2,576 | $63 |
| Short return visit (20+ min) | 33 | $2,518 | $63 |
| Destruction of precancer skin growth, 1 growth | 35 | $1,783 | $50 |
| Return visit (30+ min) | 16 | $1,244 | $78 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $592 | $30 |
| Destruction of precancer skin growth, 2-14 growths | 29 | $468 | $4 |
Medicaid work
$1,193 in 2024
Medicaid paid $1,193 for 15 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 15 | $1,193 |
| 2024 | 15 | 1 | 15 | $1,193 |
| 2023 | 12 | 1 | 12 | $365 |
| 2021 | 27 | 1 | 14 | $1,364 |
| 2020 | 12 | 1 | 12 | $795 |
| 2018 | 43 | 1 | 18 | $1,177 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 12 | $365 |
2021
| Return visit (30+ min) | 27 | $1,364 |
2020
| Return visit (30+ min) | 12 | $795 |
2018
| Short return visit (20+ min) | 43 | $1,177 |
Drugs they prescribed that Part D paid
$356,922
Pharmacies billed $356,922 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
476 generic and 57 brand-name prescriptions · $356,922 in drug cost · 13 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cosentyx Sensoready (2 Pens) | 16 | $130,893 | $8,181 |
| Dupixent | 20 | $77,410 | $3,870 |
| Tacrolimus | 16 | $2,954 | $185 |
| Clobetasol Propionate | 34 | $1,540 | $45 |
| Ketoconazole | 91 | $1,522 | $17 |
See all 14 drugs
| Cosentyx Sensoready (2 Pens) | 16 | $130,893 | $8,181 |
| Dupixent | 20 | $77,410 | $3,870 |
| Tacrolimus | 16 | $2,954 | $185 |
| Clobetasol Propionate | 34 | $1,540 | $45 |
| Ketoconazole | 91 | $1,522 | $17 |
| Fluocinonide | 32 | $1,080 | $34 |
| Metronidazole | 30 | $1,038 | $35 |
| Sulfacetamide | 11 | $709 | $64 |
| Triamcinolone Acetonide | 55 | $674 | $12 |
| Clindamycin Phosphate | 24 | $440 | $18 |
| Valacyclovir | 11 | $270 | $25 |
| Mupirocin | 16 | $166 | $10 |
| Hydrocortisone | 33 | $159 | $5 |
| Finasteride | 14 | $63 | $5 |
Year by year
| 2024 | 533 | 171 | None | 11% | $356,922 |
| 2023 | 818 | 219 | 0% (0) | 17% | $846,675 |
| 2022 | 860 | 237 | 0% (0) | 17% | $767,613 |
| 2021 | 762 | 242 | 0% (0) | 12% | $474,093 |
| 2020 | 733 | 186 | 0% (0) | 13% | $304,112 |
| 2019 | 899 | 242 | 0% (0) | None | $238,342 |
| 2018 | 849 | 254 | 0% (0) | 12% | $117,965 |
| 2017 | 141 | 68 | 0% (0) | None | $12,343 |
| 2015 | 15 | None | 0% (0) | None | $4,924 |
| 2014 | 13 | None | 0% (0) | 0% | $2,320 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Skyrizi | 11 | $245,582 | $22,326 |
| Dupixent | 26 | $97,538 | $3,751 |
| Cosentyx Sensoready (2 Pens) | 12 | $90,610 | $7,551 |
| Humira(Cf) | 12 | $88,962 | $7,414 |
| Dupixent | 12 | $46,241 | $3,853 |
| Tacrolimus | 25 | $4,656 | $186 |
| Fluocinonide | 53 | $3,147 | $59 |
| Metronidazole | 47 | $2,651 | $56 |
| Ketoconazole | 91 | $2,223 | $24 |
| Fluorouracil | 17 | $2,196 | $129 |
| Clobetasol Propionate | 28 | $1,723 | $62 |
| Triamcinolone Acetonide | 94 | $1,169 | $12 |
| Betamethasone Dipropionate | 18 | $1,113 | $62 |
| Betamethasone Diprop Augmented | 11 | $732 | $67 |
| Valacyclovir | 15 | $718 | $48 |
| Clindamycin Phosphate | 23 | $661 | $29 |
| Hydrocortisone | 70 | $506 | $7 |
| Ciclopirox | 13 | $360 | $28 |
| Mupirocin | 27 | $342 | $13 |
| Hydroxyzine | 13 | $240 | $18 |
| Finasteride | 11 | $173 | $16 |
2022: 21 drugs
| Humira(Cf) | 24 | $163,991 | $6,833 |
| Dupixent | 36 | $126,883 | $3,525 |
| Cosentyx Pen (2 Pens) | 12 | $83,715 | $6,976 |
| Jublia | 15 | $12,198 | $813 |
| Ivermectin | 12 | $5,665 | $472 |
| Clobetasol Propionate | 48 | $3,951 | $82 |
| Fluocinonide | 41 | $2,762 | $67 |
| Fluorouracil | 23 | $2,454 | $107 |
| Ketoconazole | 114 | $2,407 | $21 |
| Tacrolimus | 19 | $2,204 | $116 |
| Metronidazole | 23 | $1,840 | $80 |
| Betamethasone Dipropionate | 23 | $1,741 | $76 |
| Triamcinolone Acetonide | 108 | $1,587 | $15 |
| Clindamycin Phosphate | 34 | $1,153 | $34 |
| Betamethasone Diprop Augmented | 20 | $1,107 | $55 |
| Doxycycline Hyclate | 14 | $972 | $69 |
| Ciclopirox | 21 | $604 | $29 |
| Mupirocin | 30 | $427 | $14 |
| Hydrocortisone | 67 | $418 | $6 |
| Hydroxyzine | 26 | $187 | $7 |
| Methotrexate | 12 | $148 | $12 |
2021: 20 drugs
| Cosentyx Pen (2 Pens) | 11 | $71,128 | $6,466 |
| Dupixent | 12 | $40,599 | $3,383 |
| Jublia | 12 | $10,399 | $867 |
| Tacrolimus | 29 | $8,844 | $305 |
| Fluorouracil | 37 | $3,716 | $100 |
| Fluocinonide | 45 | $2,996 | $67 |
| Ketoconazole | 94 | $2,629 | $28 |
| Doxycycline Hyclate | 23 | $2,414 | $105 |
| Clobetasol Propionate | 35 | $2,024 | $58 |
| Metronidazole | 23 | $1,716 | $75 |
| Triamcinolone Acetonide | 122 | $1,334 | $11 |
| Betamethasone Diprop Augmented | 14 | $1,332 | $95 |
| Clindamycin Phosphate | 31 | $1,068 | $34 |
| Betamethasone Dipropionate | 13 | $885 | $68 |
| Methotrexate | 17 | $530 | $31 |
| Hydrocortisone | 54 | $429 | $8 |
| Cephalexin | 16 | $195 | $12 |
| Mupirocin | 20 | $185 | $9 |
| Ciclopirox | 11 | $173 | $16 |
| Hydroxyzine | 21 | $136 | $6 |
2020: 17 drugs
| Dupixent | 19 | $60,021 | $3,159 |
| Otezla | 13 | $47,434 | $3,649 |
| Acitretin | 12 | $8,989 | $749 |
| Tacrolimus | 22 | $5,119 | $233 |
| Metronidazole | 32 | $4,021 | $126 |
| Fluocinonide | 49 | $2,638 | $54 |
| Ketoconazole | 83 | $2,298 | $28 |
| Clobetasol Propionate | 40 | $2,227 | $56 |
| Fluorouracil | 20 | $1,589 | $79 |
| Triamcinolone Acetonide | 94 | $1,469 | $16 |
| Betamethasone Diprop Augmented | 20 | $1,441 | $72 |
| Doxycycline Hyclate | 18 | $1,048 | $58 |
| Methotrexate | 32 | $1,025 | $32 |
| Clindamycin Phosphate | 30 | $979 | $33 |
| Mupirocin | 24 | $401 | $17 |
| Hydrocortisone | 67 | $389 | $6 |
| Hydroxyzine | 16 | $137 | $9 |
2019: 18 drugs
| Humira | 21 | $109,398 | $5,209 |
| Dupixent | 11 | $32,729 | $2,975 |
| Clobetasol Propionate | 44 | $5,615 | $128 |
| Fluocinonide | 83 | $4,637 | $56 |
| Fluorouracil | 30 | $3,861 | $129 |
| Tacrolimus | 15 | $3,135 | $209 |
| Metronidazole | 35 | $2,540 | $73 |
| Ketoconazole | 115 | $2,430 | $21 |
| Methotrexate | 65 | $1,914 | $29 |
| Doxycycline Hyclate | 27 | $1,647 | $61 |
| Triamcinolone Acetonide | 104 | $1,509 | $15 |
| Clindamycin Phosphate | 51 | $1,429 | $28 |
| Hydroxychloroquine Sulfate | 18 | $811 | $45 |
| Hydrocortisone | 64 | $352 | $5 |
| Mupirocin | 32 | $303 | $9 |
| Hydroxyzine | 25 | $280 | $11 |
| Cephalexin | 14 | $119 | $8 |
| Prednisone | 15 | $106 | $7 |
2018: 18 drugs
| Tacrolimus | 20 | $5,618 | $281 |
| Fluocinonide | 62 | $4,691 | $76 |
| Doxycycline Hyclate | 60 | $4,154 | $69 |
| Clobetasol Propionate | 30 | $3,195 | $106 |
| Triamcinolone Acetonide | 158 | $2,799 | $18 |
| Ketoconazole | 85 | $2,772 | $33 |
| Metronidazole | 26 | $2,560 | $98 |
| Clindamycin Phosphate | 36 | $2,029 | $56 |
| Methotrexate | 32 | $1,485 | $46 |
| Fluorouracil | 13 | $1,480 | $114 |
| Betamethasone Diprop Augmented | 15 | $1,345 | $90 |
| Betamethasone Dipropionate | 13 | $1,201 | $92 |
| Ciclopirox | 13 | $539 | $41 |
| Mupirocin | 38 | $338 | $9 |
| Hydrocortisone | 48 | $307 | $6 |
| Prednisone | 18 | $191 | $11 |
| Hydroxyzine | 14 | $126 | $9 |
| Cephalexin | 13 | $65 | $5 |
2017: 5 drugs
| Doxycycline Hyclate | 12 | $1,512 | $126 |
| Fluocinonide | 11 | $850 | $77 |
| Ketoconazole | 27 | $790 | $29 |
| Triamcinolone Acetonide | 23 | $441 | $19 |
| Hydrocortisone | 15 | $120 | $8 |
Money from drug and device companies
$1,250 in 2024
| 2024 | 1 | 1 | $1,250 | $1,250 |
| 2023 | 1 | 2 | None | $31 |
| 2021 | 1 | 1 | $4,950 | $4,950 |
| 2020 | 2 | 2 | $4,900 | $4,900 |
| 2019 | 2 | 2 | None | $140 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genzyme | Dupixent | $1,250 | 1 payment
|
See the published payment
| Genzyme | Paid to speak or teach · 2024-07-12 | Dupixent | $1,250 |
See earlier years (2023, 2021, 2020, 2019)
2023: $31
| Pfizer | Cibinqo | $31 | 2 payments
|
2021: $4,950
| Pfizer | None | $4,950 | 1 payment
|
2020: $4,900
| Pfizer | None | $4,400 | 1 payment
|
| AbbVie | Rinvoq | $500 | 1 payment
|
2019: $140
| Novartis Pharmaceuticals | Xolair | $125 | 1 payment
|
| AbbVie | Skyrizi | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| GENZYME CORPORATION · A Randomized Double-Blind, Placebo-Controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate To Severe Atopic Dermatitis (Ad) · 2021 | Their institution | $209,815 |
| AbbVie Inc. · Rinvoq · 2020 | Their institution | $99,826 |
| AbbVie, Inc. · Rinvoq · 2019 | Their institution | $76,105 |
| GENZYME CORPORATION · A Randomized Double-Blind, Placebo-Controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate To Severe Atopic Dermatitis (Ad) · 2022 | Their institution | $63,860 |
| ABBVIE INC. · Study To Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo · 2022 | Their institution | $62,475 |
| ABBVIE INC. · A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study To Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate To Severe Atopic Dermatitis · 2021 | Their institution | $62,198 |
| ABBVIE INC. · Study To Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo · 2023 | Their institution | $32,177 |
| ABBVIE INC. · A Study of Upadacitinib in Adult Participants With Moderate-To-Severe Atopic Dermatitis and Inadequate Response To Dupilumab (Switch-Up) · 2025 | Their institution | $25,202 |
| ABBVIE INC. · Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate To Severe Atopic Dermatitis (Eczema) · 2024 | Their institution | $24,564 |
| ABBVIE INC. · A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) · 2024 | Their institution | $24,260 |
| ABBVIE INC. · A Study To Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate To Severe Atopic Dermatitis · 2025 | Their institution | $22,374 |
| ABBVIE INC. · Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate To Severe Atopic Dermatitis (Eczema) · 2023 | Their institution | $20,364 |
| ABBVIE INC. · Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate To Severe Atopic Dermatitis (Eczema) · 2022 | Their institution | $18,192 |
| ABBVIE INC. · A Study To Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate To Severe Atopic Dermatitis · 2022 | Their institution | $16,348 |
| ABBVIE INC. · A Study To Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate To Severe Atopic Dermatitis · 2023 | Their institution | $15,747 |
| ABBVIE INC. · A Study To Assess the Effect of Upadacitinib in Atopic Dermatitis-Induced Sleep Disturbance in Adults With Moderate To Severe Atopic Dermatitis (Sleep Up) · 2024 | Their institution | $15,430 |
| ABBVIE INC. · A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study To Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate To Severe Atopic Dermatitis · 2021 | Their institution | $15,136 |
| Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2022 | This clinician | $12,018 |
| ABBVIE INC. · A Study of Upadacitinib in Adult Participants With Moderate-To-Severe Atopic Dermatitis and Inadequate Response To Dupilumab (Switch-Up) · 2024 | Their institution | $11,480 |
| ABBVIE INC. · Vitiligo Is A Common Chronic Autoimmune Disease That Causes the Bodys Immune System To Attack Its Own Pigment Producing Skin Cells. This Study Is To Evaluate How Safe and Effective Upadacitinib Is in Participants With Non-Segmental Vitiligo. Adverse Effects and Change in Disease Activity Will Be Assessed. · 2022 | Their institution | $10,240 |
| ABBVIE INC. · A Study To Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate To Severe Atopic Dermatitis · 2024 | Their institution | $9,817 |
| ABBVIE INC. · Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate To Severe Atopic Dermatitis (Eczema) · 2025 | Their institution | $9,249 |
| ABBVIE INC. · M16-047 - A Study To Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate To Severe Atopic Dermatitis · 2025 | Their institution | $7,797 |
| ABBVIE INC. · Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate To Severe Atopic Dermatitis (Eczema) (Measure Up 1) · 2022 | Their institution | $5,902 |
| ABBVIE INC. · A Study To Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate To Severe Atopic Dermatitis (Ad Up) · 2022 | Their institution | $5,547 |
| ABBVIE INC. · A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study To Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy · 2024 | Their institution | $5,315 |
| Novartis Pharmaceuticals Corporation · An Exploratory, Randomized, Double-Blind, Parallel-Group, Multicenter Study To Compare Secukinumab 300 Mg With Placebo After 16 Weeks of Treatment in Adults With Moderate To Severe Plaque Psoriasis and Subclinical Enthesitis Measured By Musculoskeletal Ultrasound · 2021 | Their institution | $5,191 |
| SANOFI US SERVICES INC. · A Randomized Double-Blind, Placebo-Controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate To Severe Atopic Dermatitis (Ad) · 2022 | Their institution | $4,316 |
| ABBVIE INC. · M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) · 2025 | Their institution | $4,224 |
| ABBVIE INC. · M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate To Severe Atopic Dermatitis (Eczema) · 2025 | Their institution | $3,882 |
| GENZYME CORPORATION · A Randomized Double-Blind, Placebo-Controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate To Severe Atopic Dermatitis (Ad) · 2022 | This clinician | $3,000 |
| ABBVIE INC. · M19-044 Rinvoq Phase 3 Vitiligo · 2024 | Their institution | $2,169 |
| GENZYME CORPORATION · A Randomized Double-Blind, Placebo-Controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate To Severe Atopic Dermatitis (Ad) · 2023 | This clinician | $1,500 |
| Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2023 | This clinician | $1,344 |
| Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2021 | This clinician | $1,027 |
| GENZYME CORPORATION · A Randomized Double-Blind, Placebo-Controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate To Severe Atopic Dermatitis (Ad) · 2021 | This clinician | $750 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1609119783
- Licence
- CA A131904California A131904: Current · expires 2028-04-30
- Trained
- Harvard Medical School, 2013
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 450 Broadway, Pav C, Floor 2, Mc 5334, Redwood City, CA, 94063
- NPI first listed
- 2013-03-27
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway St Fl 2, Redwood City, CA, 94063 · 751 S Bascom Ave, San Jose, CA, 95128